Abstract:Signal transducer and activator of transcription 3 (STAT3) is frequently overexpressed in patients with acute myeloid leukemia (AML). STAT3 exists in two distinct alternatively spliced isoforms, the full-length isoform STAT3α and the C-terminally truncated isoform STAT3β. While STAT3α is predominantly described as an oncogenic driver, STAT3β has been suggested to act as a tumor suppressor. To elucidate the role of STAT3β in AML, we established a mouse model of STAT3β-deficient, MLL-AF9 -driven AML. STAT3β deficiency significantly shortened survival of leukemic mice confirming its role as a tumor suppressor. Furthermore, RNA sequencing revealed enhanced STAT1 expression and interferon (IFN) signaling upon loss of STAT3β. Accordingly, STAT3β-deficient leukemia cells displayed enhanced sensitivity to blockade of IFN signaling through both an IFNAR1 blocking antibody and the JAK1/2 inhibitor Ruxolitinib. Analysis of human AML patient samples confirmed that elevated expression of IFN-inducible genes correlated with poor overall survival and low STAT3β expression. Together, our data corroborate the tumor suppressive role of STAT3β in a mouse model in vivo. Moreover, they provide evidence that its tumor suppressive function is linked to repression of the STAT1-mediated IFN response. These findings suggest that the STAT3β/α mRNA ratio is a significant prognostic marker in AML and holds crucial information for targeted treatment approaches. Patients displaying a low STAT3β/α mRNA ratio and unfavorable prognosis could benefit from therapeutic interventions directed at STAT1/IFN signaling.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of STAT3β in acute myeloid leukemia (AML), especially its function as a tumor suppressor, and how this function improves the prognosis of AML patients by inhibiting the interferon (IFN) response. Specifically, by establishing an AML mouse model with STAT3β deletion, the researchers revealed a new function of STAT3β in inhibiting IFN signal transduction and found that this function is related to the survival rate of AML patients. In addition, the study also explored the potential value of the STAT3β/α mRNA ratio as a prognostic marker for AML and the possible benefits of treatment strategies targeting the STAT1/IFN signaling pathway for patients with a low STAT3β/α mRNA ratio. ### Main research questions: 1. **The role of STAT3β in AML**: The study aims to determine whether STAT3β has a tumor - suppressing effect, especially in AML. 2. **The relationship between STAT3β and IFN signals**: Explore how STAT3β affects the IFN signaling pathway and what significance this effect has for the biological behavior of AML cells. 3. **The clinical significance of the STAT3β/α mRNA ratio**: Evaluate whether the STAT3β/α mRNA ratio can be used as a prognostic marker for AML patients and explore its potential application in treatment. ### Research methods: - **Mouse model**: An AML mouse model with STAT3β deletion was established, and AML development was driven by the MLL - AF9 fusion gene. - **Gene expression analysis**: RNA sequencing technology was used to analyze the impact of STAT3β deletion on the gene expression of AML cells. - **Cell experiments**: The function of STAT3β was verified through in vitro experiments (such as colony - forming experiments, flow cytometry, etc.). - **Clinical data**: Samples from 79 AML patients and two publicly available RNA - sequencing data sets were analyzed to explore the relationship between the STAT3β/α mRNA ratio and patient prognosis. ### Main findings: - **The tumor - suppressing effect of STAT3β**: The survival period of mice with STAT3β deletion was significantly shortened, indicating that STAT3β has a tumor - suppressing function. - **Enhancement of IFN signals**: STAT3β deletion led to the enhancement of the IFN signaling pathway, manifested as an increase in STAT1 expression and the up - regulation of IFN - induced genes. - **The prognostic value of the STAT3β/α mRNA ratio**: A low STAT3β/α mRNA ratio was associated with a poor prognosis, and patients with high expression of STAT1 and IFN - induced genes had a poorer prognosis. - **Treatment strategies**: AML cells with STAT3β deletion were more sensitive to inhibitors of the IFN signaling pathway (such as Ruxolitinib), suggesting that these drugs may be effective for patients with a low STAT3β/α mRNA ratio. ### Conclusion: This study not only reveals new functions of STAT3β in AML but also provides a theoretical basis for the development of new treatment strategies, especially for those patients with a low STAT3β/α mRNA ratio.

A novel function of STAT3β in suppressing interferon response improves outcome in acute myeloid leukemia

STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance

Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma

[Expression and Clinical Significance of STAT3 Genes in Patients with Acute Myeloid Leukemia].

Inhibition of Stat3 Expression Induces Apoptosis and Suppresses Proliferation in Human Leukemia Hl-60 Cells

Asymmetric post-translational modifications regulate the nuclear translocation of STAT3 homodimers in response to leukemia inhibitory factor

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha

The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation

Effects of STAT3 silencing on fate of chronic myelogenous leukemia K562 cells.

Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice

Signal Transducer and Activator of Transcription 3 (STAT3) Gene Polymorphisms Are Associated with Treatment Outcomes in Acute Myeloid Leukemia

The Rs9909659g/A Polymorphisms of the Stat3 Gene Provide Prognostic Information in Acute Myeloid Leukemia

STAT3 modulates mitochondrial function and plays a critical role in the survival of leukemic stem cells

Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma

STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells.

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia

[Mechanism of Anti Apoptosis and Immune Evasion in Drug-Resistant Leukemia Cells Mediated by STAT3].

STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model

MLAA-34 Knockdown Shows Enhanced Antitumor Activity Via JAK2/STAT3 Signaling Pathway in Acute Monocytic Leukemia.

The Activator of Transcription 3 (STAT3) Gene Polymorphisms Are Associated with Treatment Outcomes In Acute Myeloid Leukemia